The effects of urine pH and plasma protein binding on the renal clearance of disopyramide
- PMID: 21054
- DOI: 10.2165/00003088-197702050-00004
The effects of urine pH and plasma protein binding on the renal clearance of disopyramide
Abstract
To ascertain whether the renal clearance of disopyramide (pKa = 8.36) is affected by urine pH, the disposition kinetics of disopyramide were compared during excretion of acidic and alkaline urine following both single dose intravenous (2mg/kg) and oral (5 mg/kg) administration to 4 healthy male volunteers. No significant difference was observed in the plasma concentration-time curve of disopyramide. The mean 72 hour recovery of disopyramide and its N-deisopropyl metabolite (MND) in urine was 55.1 and 20.3% of the dose respectively, with no apparent difference between the two routes of administration or pH of urine. Renal clearance of disopyramide was found to vary with time, which is partly the result of a concentration dependent change in plasma protein binding. The unbound fraction of drug in plasma varied from 0.32 to 0.72 between 0.4 to 4microgram/ml concentration. However, time-dependent change in renal clearance of disopyramide persists even after correction for plasma protein binding.
Similar articles
-
The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans.Int J Clin Pharmacol Ther Toxicol. 1982 May;20(5):219-26. Int J Clin Pharmacol Ther Toxicol. 1982. PMID: 7095921
-
The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide.J Pharmacokinet Biopharm. 1982 Feb;10(1):1-14. doi: 10.1007/BF01059180. J Pharmacokinet Biopharm. 1982. PMID: 7069575
-
Influence of concentration-dependent protein binding on serum concentrations and urinary excretion of disopyramide and its metabolite following oral administration.Biopharm Drug Dispos. 1983 Apr-Jun;4(2):103-12. doi: 10.1002/bdd.2510040202. Biopharm Drug Dispos. 1983. PMID: 6882879
-
Clinical pharmacokinetics of disopyramide.Clin Pharmacokinet. 1986 May-Jun;11(3):214-22. doi: 10.2165/00003088-198611030-00003. Clin Pharmacokinet. 1986. PMID: 3524956 Review.
-
Disopyramide: clinical indications, pharmacokinetics and laboratory assessment.Ann Clin Lab Sci. 1986 Jul-Aug;16(4):289-95. Ann Clin Lab Sci. 1986. PMID: 2427003 Review.
Cited by
-
Free drug concentration monitoring in clinical practice. Rationale and current status.Clin Pharmacokinet. 1986 Nov-Dec;11(6):450-69. doi: 10.2165/00003088-198611060-00003. Clin Pharmacokinet. 1986. PMID: 3542337 Review.
-
Plasma binding of disopyramide and mono-N-dealkyldisopyramide.Br J Clin Pharmacol. 1982 Nov;14(5):673-6. doi: 10.1111/j.1365-2125.1982.tb04955.x. Br J Clin Pharmacol. 1982. PMID: 7138747 Free PMC article.
-
The influence of protein binding on disopyramide clearance.Eur J Clin Pharmacol. 1982;23(5):453-6. doi: 10.1007/BF00605997. Eur J Clin Pharmacol. 1982. PMID: 7151851
-
Clinical relevance of pharmacokinetics.Clin Pharmacokinet. 1980 Mar-Apr;5(2):105-36. doi: 10.2165/00003088-198005020-00001. Clin Pharmacokinet. 1980. PMID: 6102499 Review. No abstract available.
-
Pharmacokinetics of disopyramide in patients with chronic renal failure.Eur J Drug Metab Pharmacokinet. 1983;8(1):85-92. doi: 10.1007/BF03189585. Eur J Drug Metab Pharmacokinet. 1983. PMID: 6861798
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources